insulin secretagogues peptides (incretins)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultcardiovascular eventsAll cause death

diabetes type 2

albiglutide
Seino, 2009      NCTalbiglutideplaceboExploratory negative
Rosenstock (30 mg every two weeks), 2009      NCTalbiglutide biweeklyplacebo (add on MET)Low risk of bias suggesting+Infini%
Rosenstock (30 mg weekly), 2009      NCTalbiglutide weeklyplacebo (add on MET)Exploratory suggesting
exenatide
NCT00360334    NCTexenatideglarginenegative-2%
Derosa, 2010     exenatide 20µgglibenclamidenegative
Liutkus, 2010     exenatideplacebonegative
H8O-MC-GWBJ, 9698, 10µg/d, 2008   exenatide 10µg/dplaceboLow risk of bias -
H8O-MC-GWBJ, 9698, 20µg/d, 2008   exenatide 20µg/dplaceboLow risk of bias -
Apovian, 2010     exenatide 20µg/dplaceboLow risk of bias negative
Moretto (DOUBLONS avec druker), 2008      NCTexenatide other dosesplaceboLow risk of bias negative
NCT00085969    NCTexenatide other dosesplaceboLow risk of bias -
Poon, 2005        NCTexenatide other dosesplaceboLow risk of bias -
Buse, 2011      NCTexenatide 20µg/dplacebo (add on insulin)Low risk of bias negative -100%
Fineman, 2003     exenatide other dosesplacebo (add on MER+/-SU)Exploratory -
DeFronzo 10µg/d, 2005          NCTexenatide 10µg/dplacebo (add on MET)Low risk of bias negative
DeFronzo 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on MET)Low risk of bias suggesting
Kim, 2007      NCTexenatide weeklyplacebo (add on MET)Exploratory negative
Gao, 2009      NCTexenatide 20µg/dplacebo (add on MET+/-SU)Low risk of bias suggesting -100%
Buse 10µg/d, 2004          NCTexenatide 10µg/dplacebo (add on SU)negative
Buse 20µg/d, 2004     exenatide 20µg/dplacebo (add on SU) -
Kadowaki (trial 8683), 2009     exenatide 10µg/dplacebo (add on SU+/-MET/TZD)Exploratory negative
Kendall 10µg/d, 2005      NCTexenatide 10µg/dplacebo (add on SU+MET)Low risk of bias negative
Kendall 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on SU+MET)Low risk of bias suggesting -100%
Zinman 20µg/j, 2007    NCTexenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias suggesting
Zinman 20µg/j A MODIFIER, 2007   exenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias -
Gill, 2010     exenatide 10µg/dplacebo add on MET+/-TZDLow risk of bias negative
phase 2 exenatide once monthly   exenatide once monthlyweekly exenatide -
Bergenstal (once daily), 2009     exenatide 20µg/dBIAsp 30 dailyRisk of bias -
Bergenstal (twice daily), 2009     exenatide 20µg/dBIAsp 30 twice dailyRisk of bias negative
Exenatide Trial 10749   exenatide before lunch and dinnerexenatide before breakfast and dinnerRisk of bias -
HEELA (Davies), 2009   exenatide other dosesglargine -
Heine, 2005   exenatide 20µg/dinsulin (add on SU+MET)negative 58%
Davis, 2007      NCTexenatide 20µg/dinsulin (add on SU/MET)Risk of bias negative +Infini%
Barnett, 2007      NCTexenatide 20µg/dinsulin (add on SU/MET)Exploratory suggesting
Nauck, 2007      NCTexenatide 20µg/dinsulin BIAsp twice daily add on SU+METRisk of bias negative 96%96%
DURATION-3 (Diamant), 2010    NCTexenatide weeklyinsulin glargineRisk of bias suggesting +Infini%
Bunck, 2009          NCTexenatide 20µg/dinsulin glargine (add on MET)Exploratory -
Trial 8078   exenatide other dosesinsulin glargine (add on MET/SU) -
LEAD 6 (Buse) exe vs lira, 2009     exenatide 10µg twice dailyliraglutide 1.8mg -
DURATION-2 (Bergenstal) (vs pioglitazone), 2010      NCTexenatide weeklypioglitazoneLow risk of bias suggesting-100%
DeFronzo (EXE vs ROSI), 2010     exenatide 20µg/drosiglitazone add on METExploratory negative
DURATION-2 (Bergenstal) (vs sitagliptin), 2010      NCTexenatide weeklysitagliptinLow risk of bias suggesting-100%
DeFronzo, 2008      NCTexenatide 20µg/dsitagliptin (add on MET)Low risk of bias -
Drucker, 2008      NCTexenatide 20µg/dweekly exenatide -
liraglutide
NN2211-1333     liraglutide other doses -
Pratley (1.8 vs 1.2), 2010   liraglutide 1.8mgliraglutide 1.2mgnegative
LEADER, 2016      NCTliraglutideplaceboLow risk of bias conclusive-12%-15%
Seino, 2008      NCTliraglutide other dosesplaceboExploratory negative
Madsbad (vs placebo), 2004     liraglutide other dosesplacebonegative
Harder, 2004     liraglutide other dosesplaceboExploratory -
NN2211-1571 (Vilsbøll), 2007        NCTliraglutide other dosesplaceboExploratory negative
Kaku 0.6mg, 2010     liraglutide other dosesplaceboLow risk of bias suggesting
LEAD-2 (Nauck) (1.2mg vs placebo), 2009        NCTliraglutide 1.2mgplacebo (add on MET)Low risk of bias suggesting
LEAD-2 (Nauck) (1.8mg vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on MET)Low risk of bias suggesting
NN2211-1796      NCTliraglutide other dosesplacebo (add on MET) -
LEAD-1 SU (1.2 mg vs placebo), 2009        NCTliraglutide 1.2mgplacebo (add on SU)Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on SU)Low risk of bias suggesting
LEAD-5 (vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on SU+MET)Low risk of bias suggesting 148%
LEAD-4 (1.2mg), 2009      NCTliraglutide 1.2mgplacebo (add on TZD+MET)Low risk of bias suggesting24%
LEAD-4 (1.8mg), 2009      NCTliraglutide 1.8mgplacebo (add on TZD+MET)Low risk of bias suggesting-25%
Kaku 0.9mg, 2010     liraglutide other dosesplacebo (on top SU)Low risk of bias suggesting
LEAD-6, 2009        NCTliraglutide 1.8mgexenatide on top MET/SU/MET+SURisk of bias suggesting
Seino, 2010      NCTliraglutide other dosesglibenclamideLow risk of bias negative+Infini%
LEAD-3 mono 1.2mg (Garber), 2009          NCTliraglutide 1.2mgglimepirideLow risk of bias negative -100%
LEAD-3 mono 1.8mg (Garber), 2009      NCTliraglutide 1.8mgglimepirideLow risk of bias negative
Madsbad (vs Glimepiride), 2004     liraglutide other dosesglimepirideExploratory suggesting
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009        NCTliraglutide 1.2mgglimepiride (add on MET)Low risk of bias negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009      NCTliraglutide 1.8mgglimepiride (add on MET)Low risk of bias negative
LEAD-5 (vs Glargine), 2009    NCTliraglutide 1.8mginsulin glargine (add on SU+MET)Risk of bias negative
LEAD 1 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
LEAD 2 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
LEAD 4 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
Feinglos, 2005     liraglutide other dosesmetforminExploratory negative
LEAD-1 SU (1.2 vs rosiglitazone), 2009   liraglutide 1.2mgrosiflitazonesuggesting
LEAD-1 SU (1.8 vs rosiglitazone), 2009      NCTliraglutide other dosesrosiglitazone (add on SU)Low risk of bias suggesting
Pratley 1.2mg, 2010      NCTliraglutide 1.2mgsitagliptinRisk of bias suggesting -3%-100%
Pratley 1.8mg, 2010    NCTliraglutide 1.8mgsitagliptinLow risk of bias suggesting -3%0%
lixisenatide
GETGOAL-L    NCTlixisenatideplacebo (add on basal insulin)Low risk of bias -
Ratner DRI6012, 2010      NCTlixisenatideplacebo (add on MET)Exploratory -
taspoglutide
Nauck 10 once weekly vs PBO, 2009      NCTtaspoglutide 10mg once weeklyplaceboExploratory suggesting
Nauck 20 every 2 weeks vs PBO, 2009   taspoglutide 20mg once every 2 weeksplacebosuggesting
Nauck 20 once weekly vs PBO, 2009   taspoglutide 20mg once weeklyplacebosuggesting
Ratner (20mg once weekly), 2010      NCTtaspoglutideplacebo (add on MET)Exploratory suggesting